Vireo Growth (VREOF) Operating Income (2020 - 2026)
Vireo Growth (VREOF) posted Operating Income of $9.0 million for Q1 2026, up 596.02% sequentially from -$1.8 million in Q4 2025, and up 350.0% YoY from $2.0 million in Q1 2025.
Vireo Growth (VREOF) Operating Income (2020 - 2026) Analysis & Trends
Vireo Growth has reported Operating Income for 7 years, with the latest figure at $9.0 million in Q1 2026.
- Quarterly Operating Income rose 350.0% year-over-year to $9.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.0 million (down 44.69% YoY) and the FY2025 annual result came in at -$1.0 million, down 107.73% from the prior year.
- Operating Income grew to $9.0 million in Q1 2026 per VREOF's latest filing, from -$1.8 million in the prior quarter.
- Over five years, Operating Income peaked at $9.0 million in Q1 2026 and troughed at -$7.8 million in Q1 2022.
- A 5-year average of $1.5 million and a median of $701765.0 in 2022 frame the typical range for Operating Income.
- The widest YoY moves for Operating Income: up 3204.05% in 2023, down 438.12% in 2023.
- Over 5 years, Operating Income stood at $701765.0 in 2022, then surged by 666.9% to $5.4 million in 2023, then slumped by 115.64% to -$841550.0 in 2024, then plunged by 115.61% to -$1.8 million in 2025, then soared by 596.02% to $9.0 million in 2026.
- According to Business Quant data, Operating Income over the past three periods registered $9.0 million, -$1.8 million, and $808956.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.76 Bn | 42.79 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.38 Bn | 39.73 Bn | 2.15 Bn | -231.00 Mn |
| 3 | Zoetis | 31.61 Bn | 29.93 Bn | 1.05 Bn | 837.00 Mn |
| 4 | Takeda Pharmaceutical | 28.64 Bn | 22.84 Bn | 5.10 Bn | 1.26 Bn |
| 5 | United Therapeutics | 22.20 Bn | 19.54 Bn | 683.80 Mn | 330.80 Mn |
| 6 | Viatris | 18.82 Bn | 17.93 Bn | 1.46 Bn | 6.30 Mn |
| 7 | Neurocrine Biosciences | 15.67 Bn | 15.28 Bn | 935.80 Mn | 151.50 Mn |
| 8 | Elanco Animal Health | 12.11 Bn | 11.58 Bn | 798.00 Mn | 248.00 Mn |
| 9 | Dr Reddys Laboratories | 10.10 Bn | 9.94 Bn | - | - |
| 10 | Vireo Growth | 492.80 Mn | 350.50 Mn | 95.30 Mn | -6.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 9.00 Mn |
| Dec 31, 2025 | -1.81 Mn |
| Sep 30, 2025 | 808,956.00 |
| Jun 30, 2025 | -2.02 Mn |
| Mar 31, 2025 | 2.00 Mn |
| Dec 31, 2024 | -841,550.00 |
| Sep 30, 2024 | 3.85 Mn |
| Jun 30, 2024 | 5.79 Mn |
| Mar 31, 2024 | 4.76 Mn |
| Dec 31, 2023 | 5.38 Mn |
| Sep 30, 2023 | 5.87 Mn |
| Jun 30, 2023 | -1.04 Mn |
| Mar 31, 2023 | 368,506.00 |
| Dec 31, 2022 | 701,765.00 |
| Sep 30, 2022 | -189,156.00 |
| Jun 30, 2022 | 308,185.00 |
| Mar 31, 2022 | -7.76 Mn |
| Dec 31, 2021 | -8.26 Mn |
| Sep 30, 2021 | -4.13 Mn |
| Jun 30, 2021 | -3.25 Mn |